Lymphoma (includes NHL, HL, CNS Lymphoma)

First Opinion: Liquid Biopsy Research Should Include The Perspectives Of Patients Like Me

(STAT) Mar 18, 2019 - Eleven years ago, I was shocked to be diagnosed with advanced lymphoma.

read article

Treatment Guidelines For Breast Implant-Associated Lymphoma (BIA-ALCL)

(UCCC/Colorado Cancer Blogs) Mar 12, 2019 - An article recently published in Aesthetic Surgery Journal formalizes the treatment strategy for this diagnosis, offering clear guidelines for plastic and oncologic surgeons.

read article

SMC Says ‘No’ To Novartis’ Kymriah For Adults With Lymphoma

(PharmaTimes [UK]) Mar 11, 2019 - Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.

read article

MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL

(NASDAQ) Mar 7, 2019 - MorphoSys AG today provided updates on L-MIND and B-MIND, its two ongoing clinical trials of the investigational Fc- enhanced anti-CD19 antibody MOR208 in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.

read article

TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials

(NASDAQ) Mar 8, 2019 - TG Therapeutics, Inc. today announced the successful outcome of meetings held by the independent Data Safety Monitoring Boards (DSMBs) for both the UNITY-CLL trial and for the UNITY-NHL trial.

read article

Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies

(Yahoo! Finance) Mar 7, 2019 - In subset of patients with relapsed or refractory CLL/SLL treated for over 2 years, duvelisib achieves 89% ORR and median PFS of 40 months.

read article

Imbrium Therapeutics Announces Enrollment of the First Patient in Expansion Phase of Tinostamustine Trial in Patients with Difficult-to-Treat Blood Cancers

(AP) Mar 5, 2019 - Imbrium Therapeutics L.P. today announced that they have enrolled the first patient in the expansion stage of a Phase 1/2 clinical trial of tinostamustine, an investigational treatment, in patients with relapsed refractory (R/R) hematologic malignancies in the U.S. and Europe.

read article

Butt Implants Linked To Cancer In Rare First Reported Case

(FOX News/LiveScience) Mar 1, 2019 - A woman with buttock implants was diagnosed with a rare form of cancer that, until now, has largely been linked to breast implants, according to a new report of the woman's case.

read article

Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019

(The Street) Feb 27, 2019 - Nektar Therapeutics today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the AACR Annual Meeting 2019.

read article

TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

(Markets Insider) Feb 28, 2019 - Study met the primary endpoint of Overall Response Rate (ORR). Interim data to be presented in an oral presentation at the 2019 American Association of Cancer Research (AACR) annual meeting on April 1, 2019.

read article

Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia

(Yahoo! Finance) Feb 26, 2019 - U.S. FDA grants Priority Review for REVLIMID® (lenalidomide) in combination with rituximab (R²) for previously treated follicular and marginal zone lymphoma. Prescription Drug User Fee Act action date set for June 27, 2019. Luspatercept Biologics License Application (BLA) submission timing updated to April 2019.

read article

TG Therapeutics Announces Initiation of Phase I First-in-Human Clinical Trial of its Anti-CD47/CD19 Bispecific Antibody, TG-1801, in Patients with Relapsed or Refractory B-cell Lymphoma

(Markets Insider) Feb 26, 2019 - TG Therapeutics, Inc. today announced the commencement of a Phase I first-in-human trial of TG-1801, the Company’s novel first-in-class anti-CD47/CD19 bispecific antibody, in patients with relapsed or refractory B-cell lymphoma.

read article

Lawyers Spar Over Science at Start of Second Roundup Weedkiller Trial

(Wall Street Journal) Feb 25, 2019 - California resident claims long-term use of Bayer product caused non-Hodgkin lymphoma.

read article (paid subscription required)

City of Hope Awarded Lymphoma Specialized Programs of Research Excellence (SPORE) Grant from National Cancer Institute

(City of Hope) Feb 21, 2019 - The coveted grant of $12.5 million recognizes new and diverse approaches to lymphoma prevention, detection, diagnosis and treatment.

read press release

Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

(Yahoo! Finance) Feb 21, 2019 - Gamida Cell Ltd. today announced that new data from its NAM-NK and NiCord® programs was presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research taking place in Houston, Texas.

read article

BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

(NASDAQ) Feb 19, 2019 - BeiGene, Ltd. today announced that the first patient was dosed in a global Phase 2 trial of zanubrutinib, an investigational inhibitor of Bruton's tyrosine kinase (BTK), in patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL), which BeiGene refers to as the MAGNOLIA trial.

read article

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

(StreetInsider) Feb 20, 2019 - ADC Therapeutics today announced that the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-402 (loncastuximab tesirine) in combination with Pharmacyclics LLC’s ibrutinib in patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).

read article

Torque Initiates Phase 1 Clinical Trial of TRQ-1501 Deep IL-15 Primed T Cells in Patients with Advanced Solid Tumors or Lymphomas

(The Business Journals) Feb 20, 2019 - Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that the first patient has been treated in a Phase 1 clinical trial to evaluate the safety and tolerability of TRQ-1501 Deep IL-15 Primed T cells in patients with selected relapsed or refractory solid tumors and lymphomas.

read article

FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma

(MarketWatch) Feb 18, 2019 - Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The FDA is expected to make a decision on approval by August 19, 2019. “Polatuzumab vedotin, a potential first-in-class antibody drug conjugate, in combination with bendamustine and Rituxan, improved clinical outcomes including survival in some people with relapsed or refractory diffuse large B-cell lymphoma compared to bendamustine and Rituxan alone,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We are working with the FDA to bring this important new option to patients with this aggressive disease as quickly as possible."

read article

FDA Approves Pembrolizumab for Adjuvant Treatment of Melanoma

(ASCO in Action) Feb 15, 2019 - On February 15, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Approval was based on EORTC1325/KEYNOTE‑054 (NCT02362594), a randomized, double-blind, placebo-controlled, trial in 1019 patients with completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC melanoma (AJCC 7th ed). Patients with mucosal or ocular melanoma were not eligible. Patients were randomly allocated (1:1) to receive pembrolizumab 200 mg every three weeks or placebo for up to 1 year until disease recurrence or unacceptable toxicity.

read article
Next Page